文献速递细胞病理与分子病理血液淋巴病理

EBUS-TBNA/EUS-FNA联合质谱诊断及分型淋巴结淀粉样变:两家三级中心10年经验

Role of EBUS-TBNA/EUS-FNA and mass spectrometry for diagnosis and typing of lymph node amyloidosis: 10-year experience in two tertiary care academic centers.
PubMed 文献 · Cancer Cytopathol · 2023-08-28

本研究回顾两家三级中心2011至2020年经EBUS-TBNA/EUS-FNA诊断淀粉样变的8例患者,评估该技术诊断价值及质谱分型可行性。所有病例涂片见蜡样无定形物,刚果红染色确诊;质谱分型5例为AL型、1例为重链/AL型、2例提示AL型。结论认为该技术诊断有效且提供足量材料行辅助检查包括质谱分型。

要点

  • EBUS-TBNA/EUS-FNA可有效诊断淋巴结淀粉样变并提供质谱分型材料。
  • 直接涂片或ThinPrep涂片见蜡样无定形物,刚果红染色可确诊。
  • 质谱可识别前体淀粉样蛋白,指导分型与后续管理。

核心结论

  • EBUS-TBNA/EUS-FNA可有效诊断淀粉样变并提供足量材料行质谱等辅助检查,质谱能识别前体淀粉样蛋白以助分型和管理。

研究设计与样本

  • 回顾性研究,纳入两家三级中心2011至2020年经EBUS-TBNA/EUS-FNA诊断淀粉样变的全部患者,共8例。
  • 7例行EBUS-TBNA纵隔淋巴结,1例行EUS-FNA门周淋巴结。
  • 年龄37至79岁(中位69岁),男女各半。

主要发现

  • 所有病例直接涂片(n=5)或ThinPrep涂片(n=3)见蜡样无定形物,刚果红染色确诊淀粉样变。
  • 免疫组化3例中2例显示λ轻链优势染色。
  • 质谱全部完成:5例AL型、1例重链/AL型、2例提示AL型。
  • 7例骨髓活检中3例见单克隆浆细胞、1例见淋巴浆细胞淋巴瘤。
  • 4例系统性淀粉样变中2例接受化疗且存活,3例局限性疾病观察中保持稳定。

关键数值与推荐

  • 直接涂片或ThinPrep涂片见蜡样无定形物,刚果红染色确诊淀粉样变。
  • 免疫组化3例中2例显示λ轻链优势。
  • 质谱分型:5例AL型、1例重链/AL型、2例提示AL型。

临床怎么用

  • 对疑似淋巴结淀粉样变可行EBUS-TBNA/EUS-FNA获取细胞学材料,刚果红染色确诊。
  • 细胞学材料应保留用于质谱等辅助检查以明确淀粉样蛋白前体分型。
  • 分型结果可指导系统性或局限性淀粉样变的管理决策。

局限性

  • 回顾性研究,样本量仅8例。
  • 仅来自两家三级中心,外推性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objectives of this study were to investigate the utility of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)/endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for the diagnosis of amyloidosis coupled with the feasibility of mass spectrometry (MS) for amyloid subtyping. METHODS: All patients who had amyloid diagnosed by EBUS-TBNA/EUS-FNA at two tertiary care centers from 2011 to 2020 were retrieved along with the MS subtype, clinical findings, and outcomes. RESULTS: Eight patients were included: seven underwent EBUS-TBNA of mediastinal lymph nodes, and one underwent EUS-FNA of a periportal lymph node. Ages ranged from 37 to 79 years (median, 69 years), with equal numbers of men and women. Presenting clinical history included one case each of follicular lymphoma, lymphoplasmacytic lymphoma, rheumatoid arthritis, possible sarcoid, cirrhosis, and chronic renal insufficiency, and one case each of suspected pulmonary and cardiac amyloidosis. All cases showed waxy, amorphous material on direct smears (n = 5) or ThinPrep slides (n = 3), which were confirmed as amyloid on Congo Red staining. Immunohistochemistry showed dominant lambda staining in two of three cases. MS was performed in all cases and identified five of the light-chain (AL) type, one of the heavy-chain/AL type, and two suggestive of AL amyloidosis. Bone marrow biopsy performed in seven patients demonstrated that three had monoclonal plasma cells and one had lymphoplasmacytic lymphoma. Two of four patients with systemic amyloidosis received chemotherapy and remained alive, whereas three with localized disease remained stable under observation. CONCLUSIONS: EBUS-TBNA/EUS-FNA is effective for amyloidosis diagnosis and provides adequate material for ancillary tests, including MS, which can identify the precursor amyloidogenic protein, leading to appropriate patient management.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Naqvi A, Bonert M, Finley C, et al. Role of EBUS-TBNA/EUS-FNA and mass spectrometry for diagnosis and typing of lymph node amyloidosis: 10-year experience in two tertiary care academic centers. Cancer Cytopathol. 2023. PMID: 37641237. doi:10.1002/cncy.22751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。